UroGen Pharma Ltd.
URGN
$19.67
-$0.11-0.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -154.97M | -138.43M | -126.87M | -115.38M | -113.58M |
| Total Depreciation and Amortization | 1.67M | 1.33M | 1.19M | 1.30M | 1.45M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.24M | 23.20M | 23.99M | 20.96M | 21.34M |
| Change in Net Operating Assets | 9.93M | 6.85M | 4.93M | -3.02M | 5.01M |
| Cash from Operations | -123.13M | -107.06M | -96.77M | -96.14M | -85.78M |
| Capital Expenditure | -396.00K | -339.00K | -295.00K | -236.00K | -240.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -43.29M | -59.76M | -20.32M | -92.34M | 14.81M |
| Cash from Investing | -43.69M | -60.09M | -20.61M | -92.58M | 14.57M |
| Total Debt Issued | 24.49M | 24.49M | 24.49M | 24.49M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.52M | 96.87M | 151.49M | 151.46M | 203.72M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.00K | 18.64M | 18.64M | 18.64M | 67.34M |
| Cash from Financing | 40.01M | 140.00M | 194.62M | 194.59M | 271.06M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -126.81M | -27.15M | 77.24M | 5.87M | 199.85M |